Telix Pharmaceuticals, a commercial-stage Australian biotech developing therapeutic and diagnostic radiopharmaceuticals, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company is currently listed on the Australian Securities Exchange under the symbol "TLX."
Telix Pharmaceuticals is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals, with a pipeline of candidates across urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. Its prostate cancer portfolio includes Illuccix, a commercially available gallium 68-labelled prostate-specific membrane antigen prostate cancer imaging agent. Illuccix was approved by Australia's TGA and the FDA in 2021, and Health Canada in 2022.
The North Melbourne, Australia-based company was founded in 2017 and booked $385 million in revenue for the 12 months ended March 31, 2024. It plans to list on the Nasdaq under the symbol TLX. Telix Pharmaceuticals filed confidentially on January 25, 2024. Jefferies, Morgan Stanley, Truist Securities, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
